Join the Center for Global Health Policy & Politics, the Fight AIDS Coalition, and the HIV Policy Lab for a virtual discussion on the growing threat of HIV drug resistance and effective ways to tackle this threat.
A new WHO report documented an increase in drug resistance levels, ranging from 3.9% to 19.6%, to dolutegravir. Considering the increasing evidence of drug resistance against important HIV antiretrovirals, there is a need for increased vigilance and efforts to optimize HIV care delivery.
Panelists will provide an overview of the current landscape of drug resistance to key HIV antiretroviral drugs and discuss the impact of HIV drug resistance on AIDS and advanced HIV disease. They will also highlight policies and tools to better prevent, detect, and reduce rates of HIV drug resistance and share community perspectives on HIV drug resistance, including national action and accountability and strategies for community engagement.
Speakers:
- Michael R Jordan, MD, MPH, FIDSA, Associate Professor of Medicine, Tufts University; Consultant, World Health Organization, Global HIV, Hepatitis and STIs Programmes
- Patricia Asero Ochieng, Team Leader, Dandora Community AIDS Support Association (DACASA)
- Sanjana Mukherjee, PhD, MSc, Fellow, Center for Global Health Policy & Politics, O’Neill Institute for National and Global Health Law
Moderator: Sharonann Lynch, Co-Director, Center for Global Health Policy & Politics, O’Neill Institute for National and Global Health Law